Although scientists spend a significant amount of time and effort on continuously culturing hybridoma cell lines, poor growth or even cell death still occurs occasionally. Many factors, including long-term storage, repeated freeze-thaw cycles, improper handling, and contamination can all lead to failure of hybridoma survival causing permanent loss of important monoclonal antibodies (mAbs).
In addition, hybridoma cell lines are also known to undergo gene mutations and rearrangements over time, leading to antibody heterogeneity and batch-to-batch variability. In a recent study of 185 clonal hybridoma cell lines, nearly a third were found to contain additional heavy or light chain genes resulting in impaired affinity and specificity to the target antigen. In other cases, hybridomas may even lose the chromosome containing antibody genes, completely arresting the production of antibodies.
Rapid Novor has helped hundreds of researchers recover from the loss, death or mutation of their cell lines. Starting from just a small sample of antibody protein, we can return the amino acid sequence of the mAb with 100% accuracy. From there, a limitless supply of recombinantly expressed antibodies can be produced and the sequence stored indefinitely. Many antibody users choose to sequence their most valuable mAbs as an insurance policy in case they are discontinued. Some antibody users and producers choose to confirm the sequence of every batch of antibodies produced by hybridoma as part of their validation procedures.